Compound E, chemically designated as 209986-17-4 (CAS), represents a significant study within the field of Alzheimer's condition research. This γ-secretase inhibitor was initially developed as a promising therapeutic intervention aimed at reducing the production of amyloid-beta peptides, which are believed to be critical contributors to the format